Retrospective Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 16, 2023; 11(26): 6091-6104
Published online Sep 16, 2023. doi: 10.12998/wjcc.v11.i26.6091
Multinucleated giant cells of bladder mucosa are modified telocytes: Diagnostic and immunohistochemistry algorithm and relation to PD-L1 expression score
Milena Gulinac, Tsvetelina Velikova, Dorian Dikov
Milena Gulinac, General and Clinical Pathology, Medical University of Plovdiv, Plovdiv 4002, Bulgaria
Milena Gulinac, Tsvetelina Velikova, Medical Faculty, Sofia University, St. Kliment Ohridski, Sofia 1407, Bulgaria
Dorian Dikov, Pathology, Grand Hospital de l’Este Francilien, Jossigny 1000, France
Author contributions: Gulinac M and Dikov D contributed to conceptualization, investigation, and re-sources; Gulinac M contributed to data curation; Velikova T contributed to formal analysis; Gulinac M contributed to funding acquisition and methodology; Dikov D contributed to project administration; Velikova T contributed to software; Dikov D and Velikova T contributed to supervision; Gulinac M, Dikov D, and Ve-likova T contributed to validation; Velikova T contributed to visualization; Gulinac M contributed to writing-original draft; Dikov D and Velikova T contributed to writing-re-view & editing.
Supported by the European Union-NextGenerationEU, through the National Recovery and Resilience Plan of the Republic of Bulgaria, No. BG-RRP-2.004-0008.
Institutional review board statement: The design of the study was approved by the Institutional Review Board of Department of General and Clinical Pathology, Medical University of Plovdiv (Approval No. 67/16.12.2022).
Informed consent statement: All subjects signed informed consent for the study.
Conflict-of-interest statement: The authors declare no conflict of interests.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Milena Gulinac, MD, PhD, Assistant Professor, Doctor, General and Clinical Pathology, Medical University of Plovdiv, 15A Vassil Aprilov Blvd, Plovdiv 4002, Bulgaria. mgulinac@hotmail.com
Received: June 25, 2023
Peer-review started: June 25, 2023
First decision: July 18, 2023
Revised: August 16, 2023
Accepted: August 25, 2023
Article in press: August 25, 2023
Published online: September 16, 2023
ARTICLE HIGHLIGHTS
Research background

To date, the literature lacks detailed histoepidemiological, morphological, and immunohistochemical (IHC) studies of the immunophenotype and morphogenesis of multinucleated giant cells (MGCs) in the mucosa and the stroma of the bladder. At the same time, in the non-tumor bladder, this question is insufficiently studied. These questions and difficulties, which pathologists, urologists, and oncologists are exposed to, motivated us to study these problems in more depth, using materials from two geographically different countries-Bulgaria and France.

Research motivation

We believe that it is more reasonable in the present study to determine the exact identification of these cells to use the terms: Mononuclear and MGCs present in the connective tissue of the bladder wall in neoplastic and inflammatory processes.

Research objectives

To establish the function, morphogenesis, and origin of mononuclear giant cells and MGCs in the stroma of urothelial carcinoma (UC) of the bladder in patients samples, as well as to compile a proper differential-diagnostic algorithm from histological, histochemical, and IHC criteria for the diagnosis of MGCs observed in the stroma of the UC of the bladder.

Research methods

We analyzed retrospectively urothelial bladder carcinomas (n = 104) from 2016-2020 using IHC and histochemical stain examination. Giant cells in the bladder stroma were found in 35.6% of cases, more often in high-grades.

Research results

From a pathogenetic point of view, we believe that giant stromal cells in non-tumor and tumor bladder represent a degenerative cellular phenomenon reflecting chronic mucosal bladder irritation (mechanical, chemical, or tumor in nature) and chronic mucosal inflammation. Moreover, we observed a significant correlation between these cells’ presence and the degree of tissue damage (tissue stress). From an oncological perspective, our results show that giant stromal cells in bladder UC are part of the stromal tumor response, although nonspecific and non-immune. This giant cell reaction is probably due to chronic mucosal irritation. It correlates with malignancy and the degree of tumor infiltration. In addition to the above considerations, the positive expression of p16 observed by us is further evidence of the histiocytic nature of the giant cells in the stroma of the bladder UC. In support of this, it is known from the literature that histiocytes and their derived tumor lesions are p16 positive.

Research conclusions

Based on the above results, we propose a generalized algorithm of histological, histochemical, and IHC-criteria for the diagnosis of MGCs observed in the stroma of UC of the bladder: MGCs, except in chronic cystitis and other bladder lesions, are localized in the stroma of the bladder carcinoma and the surrounding lamina propria. MGCs are 10 µm to 20 µm in size and star-shaped. Their cytoplasm is eosinophilic and sparse, with the presence of long cytoplasmic growths. The nuclei are rounded, hyperchromatic, and multilobulated, sometimes more or less atypical, but no mitotic figures are observed. Histochemically, MGCs are negative for Perls staining. Immunohistochemically, MGCs are positive for mesenchymal and myofibroblast markers (vimentin, smooth muscle actin, Desmin, and CD34), for the macrophage marker CD68, and the marker of cell aging and degeneration p16.

Research perspectives

For the first time, we showed the expression of p16 in giant stromal cells outside the context of granulomatous inflammation. This phenomenon’s probable explanation is the persistent mucosal irritation leading to this protein’s expression in an attempt to find an optimal thermodynamically and biochemically metabolic formula for stromal cells “exhausted” by chronic cellular stress. Similar “dynamic induction” in p16 expression is observed in other processes and other organs: Involution of the glandular parenchyma of the breast, wound healing, nerve regeneration, and chronic inflammation.